• Have a question?
    Open from 8am to 7pm Monday to Friday    Call customer services
    0345 54 32 600


| Print

Arbutus Biopharma Corp (ABUS)

Common Shares
Sell: $3.27|Buy: $3.36|Change: 0.05 (1.52%)

This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP

Company profile

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Address

700 West Georgia St
25th Floor
Vancouver
BC
CAN
V7Y 1B3

Telephone

+1 604 4565979

Website

http://www.arbutusbio.com

Sector 

Healthcare

Forecast key dates

NameKey Date
Arbutus Biopharma Corp Fourth Quarter Earnings Results for 20252026-03-27T00:00:00
Arbutus Biopharma Corp Annual Report for 20252026-03-27T00:00:00
Arbutus Biopharma Corp Third Quarter Earnings Conference Call for 20252025-11-06T08:45:00
Arbutus Biopharma Corp Third Quarter Earnings Results for 20252025-11-06T07:30:00
Arbutus Biopharma Corp Second Quarter Earnings Conference Call for 20252025-08-01T08:45:00
Arbutus Biopharma Corp Second Quarter Earnings Results for 20252025-08-01T00:00:00
Arbutus Biopharma Corp Annual General Meeting for 20252025-05-22T10:00:00
Arbutus Biopharma Corp First Quarter Earnings Conference Call for 20252025-05-02T08:45:00
Arbutus Biopharma Corp First Quarter Earnings Results for 20252025-05-02T00:00:00

Previous key dates

NameKey Date
Arbutus Biopharma Corp Fourth Quarter Earnings Results for 20242025-03-27T00:00:00
Arbutus Biopharma Corp Annual Report for 20242025-03-27T00:00:00
HCW @ Home with Arbutus Biopharma Corporation2024-12-03T11:00:00
Jefferies London Healthcare Conference2024-11-21T07:00:00
Arbutus Biopharma Corp Third Quarter Earnings Conference Call for 20242024-11-06T08:45:00
Arbutus Biopharma Corp Third Quarter Earnings Results for 20242024-11-06T07:30:00
H.C. Wainwright 5th Annual Viral Hepatitis Virtual Conference2024-10-08T13:30:00
Baird Global Healthcare Conference2024-09-10T08:30:00
H.C. Wainwright 26th Annual Global Investment Conference2024-09-09T08:00:00
Arbutus Biopharma Corp Second Quarter Earnings Conference Call for 20242024-08-01T08:45:00
Arbutus Biopharma Corp Second Quarter Earnings Results for 20242024-08-01T07:30:00
Arbutus to Participate in Jefferies Global Healthcare Conference2024-06-05T09:30:00
Arbutus Biopharma Corp Annual General Meeting for 20242024-05-22T10:00:00
H.C. Wainwright 2nd Annual BioConnect Investor Conference 20242024-05-20T15:30:00
The Citizens JMP Life Sciences Conference 20242024-05-14T09:30:00
Arbutus Biopharma Corp First Quarter Earnings Conference Call for 20242024-05-02T08:45:00
Arbutus Biopharma Corp First Quarter Earnings Results for 20242024-05-02T07:30:00

AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.

© Copyright 2025 AJ Bell. All rights reserved.